Caricamento...
Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
Background: Differentiated thyroid cancers (DTC) make up 95% of all thyroid cancers. Radioactive iodine therapy (RAI Rx) is an integral part of DTC management. However, 5-15% of DTC and 50% of metastatic DTC become resistant to RAI Rx and carries a 10-year survival of only 10%. One of the newer ther...
Salvato in:
| Pubblicato in: | J Endocr Soc |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8090069/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1833 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|